Neumora Therapeutics (NMRA) Expected to Announce Quarterly Earnings on Tuesday

Neumora Therapeutics (NASDAQ:NMRA) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. On average, analysts expect Neumora Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neumora Therapeutics Trading Up 0.7 %

NASDAQ NMRA opened at $0.76 on Tuesday. The company’s fifty day simple moving average is $1.09 and its 200-day simple moving average is $5.54. Neumora Therapeutics has a 52 week low of $0.62 and a 52 week high of $17.19. The stock has a market cap of $123.35 million, a P/E ratio of -0.41 and a beta of 2.89.

Analysts Set New Price Targets

A number of research analysts have recently commented on NMRA shares. Stifel Nicolaus cut shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. William Blair lowered shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, March 10th. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Bank of America reiterated an “underperform” rating and set a $1.00 target price (down previously from $7.00) on shares of Neumora Therapeutics in a research note on Wednesday, April 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $5.00 target price on shares of Neumora Therapeutics in a research note on Thursday, April 10th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Neumora Therapeutics has a consensus rating of “Hold” and a consensus price target of $9.29.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.